KS
Kazutaka Shimoda
Director, Managing Executive Officer, Head of Research & Development
JCR PharmaceuticalsJCR Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| IZCARGO® (pabinafusp alfa) | Mucopolysaccharidosis II (Hunter syndrome) | Approved |
| JR-141 (pabinafusp alfa) | Mucopolysaccharidosis II (Hunter syndrome) | Phase 3 |
| JR-171 (lepunafusp alfa) | Mucopolysaccharidosis I (with CNS involvement) | Phase 1/2 |
| JR-441 | Sanfilippo syndrome Type A (MPS IIIA) | Preclinical |
| JR-161 | Tay-Sachs/Sandhoff disease | Preclinical |
Leadership Team at JCR Pharmaceuticals
SA
Shin Ashida
Representative Director, President & CEO
KA
Katsuhiko Asano
Director, Senior Managing Executive Officer
HY
Hiroshi Yagi
Director, Senior Managing Executive Officer, Head of Quality & Manufacturing
YK
Yoshikazu Kato
Director, Managing Executive Officer, Head of Corporate Strategy & Administration
HK
Hironori Kawasaki
Director, Managing Executive Officer, Head of Sales & Marketing
KO
Koji Okamoto
Director, Executive Officer
TS
Toshihiro Shibayama
Director, Executive Officer, Head of Business Development
MA
Masanori Aoki
Director, Executive Officer
YO
Yoshihiko Ohtani
Standing Corporate Auditor
YM
Yoshihiro Matsumura
Corporate Auditor